336 related articles for article (PubMed ID: 33177720)
21. Bladder cancer in 2017: Advancing care through genomics and immune checkpoint blockade.
Galsky MD
Nat Rev Urol; 2018 Feb; 15(2):71-72. PubMed ID: 29182606
[No Abstract] [Full Text] [Related]
22. [Not Available].
Caux C; Bay JO
Bull Cancer; 2018 Dec; 105 Suppl 1():S1-S2. PubMed ID: 30595190
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
24. Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.
Pérez-Ruiz E; Etxeberria I; Rodriguez-Ruiz ME; Melero I
Clin Cancer Res; 2017 Sep; 23(18):5326-5328. PubMed ID: 28790118
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoint inhibitors in lung cancer: an update.
Sullivan K; Preeshagul I; Budman D; Seetharamu N
Future Oncol; 2017 May; 13(11):955-959. PubMed ID: 28481150
[No Abstract] [Full Text] [Related]
26. Inferior outcomes in immunocompromised Merkel cell carcinoma patients: Can they be overcome by the use of PD1/PDL1 inhibitors?
Dasanu CA; Del Rosario M; Codreanu I; Hyams DM; Plaxe SC
J Oncol Pharm Pract; 2019 Jan; 25(1):214-216. PubMed ID: 29933728
[TBL] [Abstract][Full Text] [Related]
27. Harnessing immune checkpoints for cancer therapy.
Vinay DS; Kwon BS
Immunotherapy; 2018 Oct; 10(14):1265-1284. PubMed ID: 30326786
[TBL] [Abstract][Full Text] [Related]
28. Microbiota-Regulated Outcomes of Human Cancer Immunotherapy via the PD-1/PD-L1 Axis.
Patel J; Crawford JM
Biochemistry; 2018 Feb; 57(6):901-903. PubMed ID: 29350031
[No Abstract] [Full Text] [Related]
29. Biomarkers of response to immune checkpoint blockade in cancer treatment.
Fujii T; Naing A; Rolfo C; Hajjar J
Crit Rev Oncol Hematol; 2018 Oct; 130():108-120. PubMed ID: 30196907
[TBL] [Abstract][Full Text] [Related]
30. Making cancer immunotherapy a surer bet.
Eisenstein M
Nature; 2017 Dec; 552(7685):S72-S73. PubMed ID: 29293218
[No Abstract] [Full Text] [Related]
31. Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model.
Wu Y; Lin L; Shen Y; Wu H
Int J Cancer; 2018 Dec; 143(11):3038-3040. PubMed ID: 29987914
[No Abstract] [Full Text] [Related]
32. Part I: Checkpoint inhibitors in cancer therapy.
Daud AI
Immunotherapy; 2016 Jun; 8(6):675-6. PubMed ID: 27197535
[No Abstract] [Full Text] [Related]
33. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
Šmahel M
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
[TBL] [Abstract][Full Text] [Related]
34. Nanobody against PDL1.
Li S; Jiang K; Wang T; Zhang W; Shi M; Chen B; Hua Z
Biotechnol Lett; 2020 May; 42(5):727-736. PubMed ID: 32006351
[TBL] [Abstract][Full Text] [Related]
35. Selection of PD1/PD-L1 X-Aptamers.
Wang H; Lam CH; Li X; West DL; Yang X
Biochimie; 2018 Feb; 145():125-130. PubMed ID: 28912094
[TBL] [Abstract][Full Text] [Related]
36. Progress of immune checkpoint therapy in the clinic (Review).
Fan Y; Zhang C; Jin S; Gao Z; Cao J; Wang A; Li D; Wang Q; Sun X; Bai D
Oncol Rep; 2019 Jan; 41(1):3-14. PubMed ID: 30365127
[TBL] [Abstract][Full Text] [Related]
37. Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection.
Iivanainen S; Koivunen JP
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31952311
[TBL] [Abstract][Full Text] [Related]
38. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
39. Checkpoint blockade after kidney transplantation.
Lesouhaitier M; Dudreuilh C; Tamain M; Kanaan N; Bailly E; Legoupil D; Deltombe C; Perrin P; Manson G; Vigneau C; Houot R
Eur J Cancer; 2018 Jun; 96():111-114. PubMed ID: 29705511
[No Abstract] [Full Text] [Related]
40. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
